Pharma Sources Insight第三期：聚焦2020中國(guó)制藥行業(yè)發(fā)展現(xiàn)狀

熱門推薦：中國(guó)制藥行業(yè) , 電子匯編 , Pharma Sources Insight ,

來(lái)源：CPHI制藥在線

2023-04-28

本期Pharma Sources Insight旨在介紹2020年中國(guó)制藥行業(yè)在原料藥、腫瘤藥物研發(fā)、基因工程及智能制造等領(lǐng)域的新趨勢(shì)及藥企研發(fā)進(jìn)展，盤點(diǎn)國(guó)內(nèi)制藥行業(yè)重要領(lǐng)域的發(fā)展現(xiàn)狀。

PharmaSources.com平臺(tái)制藥行業(yè)原創(chuàng)內(nèi)容電子匯編——《Pharma Sources Insight》第三期上線了！

Pharma Sources Insight第三期

2020年，在全球抗疫的背景下，制藥行業(yè)在研發(fā)新冠**及治療方案等各方面都取得了突破性的進(jìn)展。與此同時(shí)，疫情的發(fā)展影響到了全球制藥行業(yè)從原料藥生產(chǎn)、創(chuàng)新藥研發(fā)乃至制藥物流供應(yīng)鏈的各個(gè)方面。本期Pharma Sources Insight旨在介紹2020年中國(guó)制藥行業(yè)在原料藥、腫瘤藥物研發(fā)、基因工程及智能制造等領(lǐng)域的新趨勢(shì)及藥企研發(fā)進(jìn)展，盤點(diǎn)國(guó)內(nèi)制藥行業(yè)重要領(lǐng)域的發(fā)展現(xiàn)狀。

12月16日-18日，制藥工業(yè)壓軸盛會(huì)--CPhI & P-MEC China 2020展會(huì)將于上海新國(guó)際博覽中心隆重舉行。本期Pharma Sources Insight采訪到其中3家優(yōu)質(zhì)參展商、他們同時(shí)也是PharmaSources.com線上平臺(tái)會(huì)員，分別是：

派亞集團(tuán)旗下的淄博程明化工設(shè)備有限公司

Shandong Charming Chemical Equipment Co., Ltd. under Pioneer Group

漢瑞藥業(yè)（荊門）有限公司

Hiray pharmaceutical（Jingmen）Co.,LTD

上海飛瑞國(guó)際貨運(yùn)代理有限公司

InterMax Logistics Solution Limited

在“Brand Story”品牌故事欄目中，他們將介紹各自企業(yè)的優(yōu)勢(shì)及特色產(chǎn)品，分享其在抗疫過(guò)程中如何克服重重困難，為客戶提供解決方案的故事。

《Pharma Sources Insight》致力于為制藥行業(yè)經(jīng)歷的每個(gè)重要亮點(diǎn)書寫新的篇章。2020年，Pharma Sources Insight共推出了三期，主題分別為后疫情時(shí)代（Post-pandemic Future）、療愈的征程(The Great Journey of Recovery)及制藥中國(guó)說(shuō)(The Pharma Landscape in China)，收獲了制藥人的喜愛與支持。

因?yàn)橛辛俗x者的鼓勵(lì)，作為制藥全產(chǎn)業(yè)鏈線上服務(wù)平臺(tái)--制藥在線（CPhI.CN）的國(guó)際站，PharmaSources.com將繼續(xù)秉持原創(chuàng)宗旨，攜旗下資深的海外專家撰稿人，為全球制藥人士帶來(lái)更多專業(yè)深度的優(yōu)質(zhì)內(nèi)容。我們會(huì)繼續(xù)努力，敬請(qǐng)期待！

掃碼開始閱讀

Scan to view the full contents.

Pharma Sources Insight

掃碼開始閱讀

Your FREE source of news and insights into China pharmaceutical industry

Pharma Sources Insight is a unique source of updated coverages on current events and deep insights into hot areas of the pharma industry, from China to the world. It follows up new developments with those among the leading drug-manufacturers in China which further affect the world.

Now, join PharmaSources.com to get access to news of the Chinese pharmaceutical enterprises and to witness industrial changes through the exclusive perspectives of our expert writers into crucial aspects of the pharmaceutical field, all under PharmaSources.com and CPhI China.

Contents：

Pharma Sources Insight October 2020 focuses on the following topics:

PHARMA IN CHINA

- Trends in China’s Pharmaceutical Industry in 2020

- Chinese APIs and Their Role in the World’s Pharmaceutical Industry

- Chinese Pharma Firms Can Support Africa Reduce Import Bill

- Insights Into the Oncology Landscape in China

- The Impact of the Human Genome Project on China Pharmaceutical Industry 20 Years Later

- A Comparison of Top Ten Best-Selling Oncology Drugs in China and the U.S. in 2019

- Which Will Go Further? Innovent or Junshi?

- Production Applications of Chinese New Drugs in 2020 H1: Five Class 1 New Chemical Drugs, Two Anti-PD-1 Monoclonal Antibodies and Two CAR T-Cell Products Applied for Production for the First Time

Brand Story

- PIONEER SPEED - Charming Fully Support All the Pharmaceutical Companies to Fight Against COVID-19

- Hiray Pharmaceutical, API CDMO and Antiviral API R&D Center

- An Opportunity for Pharmaceuticals Logistics During the Special Period : Cold Chain Rail Transport

Industry Insight

- A Smarter Pharma Industry: The Key to Addressing Challenges During the COVID-19 Pandemic

Previous Review